DUBLIN--(BUSINESS WIRE)--The "Research Report on China's Nicorandil Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

The rising number of patients with coronary heart disease in China has contributed to the growth of the market.

Nicorandil is an anti-anginal drug that both relieves angina symptoms and improves the prognosis of coronary artery disease, with both nitrate-like effects and ATP-sensitive potassium channel-opening effects. It can both dilate large coronary arteries and diastole coronary microcirculatory resistance vessels, increasing coronary blood flow and myocardial oxygen supply while decreasing myocardial oxygen consumption, which effectively relieve angina pectoris. Several global medication guidelines have made high-level recommendations for Nicorandil.

Nicorandil was developed by Chugai with SIGMART as its trade name. Nicorandil tablets were launched in Japan in 1984 as an anti-anginal drug while the injection was put into clinical use for unstable angina in 1993 and acute heart failure in 2007. Nicorandil from Chugai entered the Chinese market in 2009, and generic drugs from local Chinese companies have been marketed since then. in 2017, Nicorandil became reimbursable under the Chinese medical insurance.

The publisher's survey data show that from 2016 to 2020, the sales value of nicorandil in the Chinese market kept increasing year by year. Even in the face of COVID-19, the sales value still achieved growth in 2020, reaching CNY428 million, with a CAGR of 85% from 2016 to 2020. The dosage forms of nicorandil sold in China include tablets and injection, with the latter already occupying the major market share in terms of sales value.

The publisher expects that from 2021 to 2025, the number of patients with coronary heart disease and angina will continue to rise in China, and the demand for nicorandil in the Chinese market will keep growing.

Topics Covered:

• The Impact of COVID-19 on China's Nicorandil Market
• Development Environment of Nicorandil in China
• Sales Volume of Nicorandil in China
• Sales Volume and Value of Nicorandil in China by Region
• Major Nicorandil Manufacturers in China and Their Market Share
• Sales Price of Nicorandil in China
• Prospects of China's Nicorandil Market, 2021-2025

Key Topics Covered:

1 Relevant Concept of Nicorandil

1.1 Indications of Nicorandil

1.2 Development of China's Nicorandil Market

1.3 Governmental Approval of Nicorandil in China

1.4 The Impact of COVID-19 on China's Nicorandil Market

2 Sales of Nicorandil in China, 2016-2020

2.1 Sales Value

2.1.1 Sales Value in China

2.1.2 Sales Value in China by Region

2.2 Sales Volume

2.2.1 Sales Volume in China

2.2.2 Sales Volume in China by Region

2.3 Sales of Nicorandil in China by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Tablets

3 Analysis of Major Nicorandil Manufacturers in China, 2020

3.1 Analysis of Market Share

3.1.1 Market Share of Manufacturers by Sales Value

3.1.2 Market Share of Manufacturers by Sales Volume

3.2 Beijing Sihuan Kebao Pharmaceutical Co., Ltd.

3.2.1 Company Profile

3.2.2 Sales of Nicorandil in China

3.3 Chugai Pharmaceutical Co., Ltd.

3.3.1 Company Profile

3.3.2 Sales of Nicorandil in China

3.4 Xi'an Hanfeng Pharmaceutical Co., Ltd.

3.4.1 Company Profile

3.4.2 Sales of Nicorandil in China

3.5 Henan Topfond Pharmaceutical Co., Ltd.

3.5.1 Company Profile

3.5.2 Sales of Nicorandil in China

3.6 Shanxi Xin Yu Pharmaceutical Co., Ltd.

3.6.1 Company Profile

3.6.2 Sales of Nicorandil in China

4 Sales Price of Nicorandil of Different Companies in China, 2020-2021

4.1 Beijing Sihuan Kebao Pharmaceutical Co., Ltd. (RuiKeXi)

4.2 Chugai Pharmaceutical Co., Ltd. (SIGMART)

4.3 Xi'an Hanfeng Pharmaceutical Co., Ltd. (XinDiPin)

4.4 Henan Topfond Pharmaceutical Co., Ltd. (TianFang)

4.5 Shanxi Xin Yu Pharmaceutical Co., Ltd. (YiWanKang)

5 Prospects of China's Nicorandil Market, 2021-2025

5.1 Influencing Factors for the Market Development

5.1.1 The Impact of COVID-19 on the Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/ubgxzz

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900